Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients
Status:
Completed
Trial end date:
2013-03-27
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine whether erenumab is safe and well tolerated
in healthy adults and migraine patients. As part of the secondary objectives, this study will
be conducted to characterize the pharmacokinetic (PK) profile of erenumab after single
subcutaneous (SC) or intravenous (IV) doses in healthy participants and migraine patients as
well as to characterize the effect of erenumab on the capsaicin-induced increase in dermal
blood flow after single SC or IV doses in healthy participants and migraine patients.